Attenuating tumor necrosis factor α does not ameliorate other cytokine and peroxidase products during sepsis

American Journal of Surgery

Volumn 178, Issue 6, 1999, Pages 556-558

  Mazolewski, Peter J ^a   Barber, Annabel ^a   Williams, Shelley ^a   Simoni, Jan ^a   Davis, Shawn ^a   Shires, G Tom ^a  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BB 1101; CYTOKINE; INTERLEUKIN 6; LIPID HYDROPEROXIDE; MALONALDEHYDE; MATRIX METALLOPROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEPSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0033392916     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(99)00216-0     Document Type: Article

References (12)

1. Beutler B., Milsark I.W., Cerami A. Passive immunization against cachetin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 229:1985;869-891.
2. Tracey K.J., Beutler B., Lowry S.F., et al. Shock and tissue injury induced by recombinant human cachectin. Science. 234:1986;470-474.
3. Tracey K.J., Fong Y., Hesse D.G., et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia in baboons. Nature. 330:1987;662.
4. Tracey K.J., Lowry S.F., Fahey T.J. III, et al. Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet. 164:1987;415.
5. Fisher J.C.J., Opal S.M., Dhainaut J.F., et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med. 21:1993;318-327.
6. Dhainaut J.F.A., Vincent J.L., Richard C., et al. CDP571, a humanized antibody to human tumor necrosis factor-α safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock . Crit Care Med. 23:1995;1461-1469.
7. Fisher J.C.J., Slotman G.J., Opal S.M., et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome a randomized open-label, placebo-controlled multicenter trial . Crit Care Med. 22:1994;12-21.
8. Fisher C.J. Jr, Dhainaut J.-F., Opal S.M., et al. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome results from a randomized, double-blind placebo-controlled trial . JAMA. 271:1994;1836-1843.
9. Gearing A.J.H., Beckett P., Christodoulou M., et al. Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature. 370:1994;555-557.
10. Van Zee K.J., Kohno T., Fischer E., et al. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive TNFα in vitro and in vivo. Proc Natl Acad Sci USA. 89:1992;4845-4849.
11. Ohkawa H., Ohishi N., Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reduction. Analyt Biochem. 95:1979;351-358.
12. Simoni J., Simoni G., Garcia E.L., et al. Protective element of selenium on hemoglobin mediated lipid peroxidation in vivo. Artific Cell Blood Subs Immobil Biotechnol. 23:1995;459-486.